A naukri.com initiative
Bioengineer
7d
215
Image Credit: Bioengineer
ctDNA Uncovers Resistance in Metastatic NSCLC Therapy
- The use of circulating tumour DNA (ctDNA) in metastatic non-small-cell lung cancer (NSCLC) research has become crucial in understanding and overcoming acquired resistance to targeted therapies.
- While targeted therapies have significantly improved outcomes for NSCLC patients with specific oncogenic mutations, acquired resistance poses a major challenge to long-term treatment efficacy.
- ctDNA analysis has emerged as a valuable tool for detecting resistance mechanisms early, such as secondary mutations, bypass pathway activations, and histological transformations.
- Traditional tumor biopsies are invasive and may not capture tumor heterogeneity effectively, making ctDNA a preferred non-invasive alternative for monitoring disease dynamics and genetic evolution.
- Studies have shown that ctDNA can detect emerging resistance mutations before radiographic progression, allowing for timely intervention with appropriate inhibitors like osimertinib in EGFR-mutant NSCLC.
- Challenges in utilizing ctDNA include methodological variations, technical limitations, and interpreting complex mutational landscapes, necessitating rigorous analytical approaches for accurate interpretation.
- Future directions involve designing informative ctDNA-based trials with harmonized methodologies to elucidate the temporal evolution of resistance and guide personalized therapeutic strategies.
- Integrating ctDNA analysis with other modalities like circulating tumor cells and advanced imaging offers a more comprehensive understanding of resistance mechanisms and tumor biology.
- Despite challenges, ongoing efforts aim to standardize ctDNA study designs, enhance assay technologies, and educate clinicians for seamless integration into precision oncology decision-making.
- The ultimate goal of ctDNA research in NSCLC is to transform the disease into a manageable chronic condition through adaptive therapies informed by real-time molecular insights.
- Continued innovation and validation of ctDNA approaches hold promise in revolutionizing how oncologists detect resistance, tailor therapy, and enhance survival outcomes for metastatic NSCLC patients.
Read Full Article
12 Likes
For uninterrupted reading, download the app